Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
SCLN's Cash to Debt is ranked higher than
98% of the 811 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. SCLN: No Debt )
SCLN' s 10-Year Cash to Debt Range
Min: 2.83   Max: No Debt
Current: No Debt

Equity to Asset 0.87
SCLN's Equity to Asset is ranked higher than
93% of the 757 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. SCLN: 0.87 )
SCLN' s 10-Year Equity to Asset Range
Min: 0.52   Max: 0.94
Current: 0.87

0.52
0.94
Interest Coverage 101.25
SCLN's Interest Coverage is ranked higher than
68% of the 491 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 97.33 vs. SCLN: 101.25 )
SCLN' s 10-Year Interest Coverage Range
Min: 34.65   Max: 9999.99
Current: 101.25

34.65
9999.99
F-Score: 7
Z-Score: 11.30
M-Score: -2.81
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 16.73
SCLN's Operating margin (%) is ranked higher than
87% of the 787 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.15 vs. SCLN: 16.73 )
SCLN' s 10-Year Operating margin (%) Range
Min: -17400   Max: 26.31
Current: 16.73

-17400
26.31
Net-margin (%) 17.73
SCLN's Net-margin (%) is ranked higher than
91% of the 787 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.39 vs. SCLN: 17.73 )
SCLN' s 10-Year Net-margin (%) Range
Min: -17900   Max: 24.77
Current: 17.73

-17900
24.77
ROE (%) 15.15
SCLN's ROE (%) is ranked higher than
90% of the 796 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.47 vs. SCLN: 15.15 )
SCLN' s 10-Year ROE (%) Range
Min: -184.28   Max: 30.21
Current: 15.15

-184.28
30.21
ROA (%) 12.85
SCLN's ROA (%) is ranked higher than
95% of the 815 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.13 vs. SCLN: 12.85 )
SCLN' s 10-Year ROA (%) Range
Min: -136.57   Max: 25.6
Current: 12.85

-136.57
25.6
ROC (Joel Greenblatt) (%) 72.31
SCLN's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 811 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.76 vs. SCLN: 72.31 )
SCLN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -632   Max: 99.26
Current: 72.31

-632
99.26
Revenue Growth (%) 10.30
SCLN's Revenue Growth (%) is ranked higher than
77% of the 661 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. SCLN: 10.30 )
SCLN' s 10-Year Revenue Growth (%) Range
Min: -4.7   Max: 135.1
Current: 10.3

-4.7
135.1
EBITDA Growth (%) -19.00
SCLN's EBITDA Growth (%) is ranked higher than
55% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. SCLN: -19.00 )
SCLN' s 10-Year EBITDA Growth (%) Range
Min: -53.8   Max: 13.5
Current: -19

-53.8
13.5
EPS Growth (%) -22.50
SCLN's EPS Growth (%) is ranked higher than
60% of the 627 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. SCLN: -22.50 )
SCLN' s 10-Year EPS Growth (%) Range
Min: -58.7   Max: 132.1
Current: -22.5

-58.7
132.1
» SCLN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

SCLN Guru Trades in Q3 2013

Steven Cohen 22,664 sh (New)
Jim Simons 506,100 sh (+272.68%)
Chuck Royce 13,700 sh (+17.09%)
Paul Tudor Jones 28,100 sh (+8.91%)
» More
Q4 2013

SCLN Guru Trades in Q4 2013

John Burbank 13,513 sh (New)
Paul Tudor Jones 35,700 sh (+27.05%)
Chuck Royce 13,700 sh (unchged)
Steven Cohen Sold Out
Jim Simons 234,904 sh (-53.59%)
» More
Q1 2014

SCLN Guru Trades in Q1 2014

Jim Simons 263,007 sh (+11.96%)
Chuck Royce 15,100 sh (+10.22%)
John Burbank Sold Out
Paul Tudor Jones Sold Out
» More
Q2 2014

SCLN Guru Trades in Q2 2014

Jim Simons 321,326 sh (+22.17%)
Chuck Royce 15,100 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with SCLN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2014-03-31 Sold Out $4.34 - $5.3 $ 7.963%0
John Burbank 2013-12-31 New Buy$4.37 - $5.26 $ 7.965%13513
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 18.80
SCLN's P/E(ttm) is ranked higher than
90% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 41.30 vs. SCLN: 18.80 )
SCLN' s 10-Year P/E(ttm) Range
Min: 6.29   Max: 189.41
Current: 18.8

6.29
189.41
P/B 2.62
SCLN's P/B is ranked higher than
71% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.31 vs. SCLN: 2.62 )
SCLN' s 10-Year P/B Range
Min: 0.82   Max: 6.15
Current: 2.62

0.82
6.15
P/S 3.34
SCLN's P/S is ranked higher than
69% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. SCLN: 3.34 )
SCLN' s 10-Year P/S Range
Min: 0.67   Max: 12.41
Current: 3.34

0.67
12.41
PFCF 15.80
SCLN's PFCF is ranked higher than
94% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SCLN: 15.80 )
SCLN' s 10-Year PFCF Range
Min: 3.83   Max: 458
Current: 15.8

3.83
458
EV-to-EBIT 14.90
SCLN's EV-to-EBIT is ranked higher than
90% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.86 vs. SCLN: 14.90 )
SCLN' s 10-Year EV-to-EBIT Range
Min: -55.9   Max: 207.3
Current: 14.9

-55.9
207.3
Shiller P/E 24.67
SCLN's Shiller P/E is ranked higher than
82% of the 835 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 96.41 vs. SCLN: 24.67 )
SCLN' s 10-Year Shiller P/E Range
Min: 15.13   Max: 218.5
Current: 24.67

15.13
218.5
Current Ratio 6.06
SCLN's Current Ratio is ranked higher than
91% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. SCLN: 6.06 )
SCLN' s 10-Year Current Ratio Range
Min: 1.32   Max: 12.59
Current: 6.06

1.32
12.59
Quick Ratio 5.37
SCLN's Quick Ratio is ranked higher than
90% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. SCLN: 5.37 )
SCLN' s 10-Year Quick Ratio Range
Min: 1.05   Max: 12.59
Current: 5.37

1.05
12.59

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.37
SCLN's Price/Net Cash is ranked higher than
96% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SCLN: 6.37 )
SCLN' s 10-Year Price/Net Cash Range
Min: 2.06   Max: 343.8
Current: 6.37

2.06
343.8
Price/Net Current Asset Value 4.11
SCLN's Price/Net Current Asset Value is ranked higher than
96% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SCLN: 4.11 )
SCLN' s 10-Year Price/Net Current Asset Value Range
Min: 1.19   Max: 225
Current: 4.11

1.19
225
Price/Tangible Book 3.39
SCLN's Price/Tangible Book is ranked higher than
78% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.93 vs. SCLN: 3.39 )
SCLN' s 10-Year Price/Tangible Book Range
Min: 0.84   Max: 17.88
Current: 3.39

0.84
17.88
Price/DCF (Projected) 1.14
SCLN's Price/DCF (Projected) is ranked higher than
93% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.00 vs. SCLN: 1.14 )
SCLN' s 10-Year Price/DCF (Projected) Range
Min: 0.69   Max: 6.05
Current: 1.14

0.69
6.05
Price/Median PS Value 1.37
SCLN's Price/Median PS Value is ranked higher than
68% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.25 vs. SCLN: 1.37 )
SCLN' s 10-Year Price/Median PS Value Range
Min: 0.26   Max: 138.75
Current: 1.37

0.26
138.75
Price/Graham Number 1.64
SCLN's Price/Graham Number is ranked higher than
88% of the 837 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.08 vs. SCLN: 1.64 )
SCLN' s 10-Year Price/Graham Number Range
Min: 0.68   Max: 4.95
Current: 1.64

0.68
4.95
Earnings Yield (Greenblatt) 6.70
SCLN's Earnings Yield (Greenblatt) is ranked higher than
82% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.90 vs. SCLN: 6.70 )
SCLN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 482.2
Current: 6.7

0.5
482.2
Forward Rate of Return (Yacktman) 3.46
SCLN's Forward Rate of Return (Yacktman) is ranked higher than
76% of the 683 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. SCLN: 3.46 )
SCLN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -39.9   Max: 49
Current: 3.46

-39.9
49

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:SPJ.Germany
SciClone Pharmaceuticals, Inc., a Delaware corporation was incorporated in 1990. The Company is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. The Company's primary product, ZADAXIN (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), as a vaccine adjuvant, and certain cancers according to the local regulatory approvals. It markets approximately 14 partnered products in China, including Depakine, a prescribed broad-spectrum anti-convulsant in China; Tritace, an ACE inhibitor for the treatment of hypertension; Stilnox, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien in the US); and Aggrastat, an interventional cardiology product. The Company operates is two segments based on the nature and locations of its customers: China and the rest of the world which includes its US and Hong Kong operations. It competitors for existing and future products include pharmaceutical companies, biotechnology firms, universities and other research institutions, in the US, China and other territories, that are actively engaged in research and development or marketing of products in the therapeutic areas the Company is pursuing. The Company's products in clinical development in the US, China and other foreign countries are subject to approval by the FDA, the SFDA and similar regulatory authorities.
» More Articles for SCLN

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: V, SCLN, VR, AMSG Jun 25 2012 
comment on SCLN Apr 29 2012 
SciClone Pharmaceuticals Inc. Reports Operating Results (10-K/A) Dec 06 2010 
SciClone Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
SciClone Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2009 
SciClone Pharmaceuticals Inc. (SCLN) CEO Friedhelm Blobel buys 10,000 Shares May 26 2009 
SciClone Pharmaceuticals Inc. (SCLN) CFO Gary Titus buys 4,625 Shares May 26 2009 
Consumers Are Protected When Purchasing Service Contracts Dec 13 2008 

More From Other Websites
SciClone to Present at BioCentury NewsMakers in the Biotech Industry Conference on September 26,... Sep 17 2014
SciClone to Present at Aegis 2014 Healthcare & Technology Conference on September 11, 2014 Sep 03 2014
SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 28 2014
SciClone and BTG Announce That DC Bead(R) Has Been Approved by China Food and Drug Administration Aug 28 2014
SCICLONE PHARMACEUTICALS INC Financials Aug 19 2014
SciClone Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today Aug 11 2014
SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 11 2014
SciClone Reports Financial Results for the Second Quarter 2014 Aug 11 2014
Q2 2014 SciClone Pharmaceuticals Inc Earnings Release - After Market Close Aug 11 2014
SciClone Pharmaceuticals to Report Financial Results for the Second Quarter 2014 on August 11th Jul 31 2014
SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 13 2014
Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); $5.50 Price Target Jun 11 2014
SciClone to Present at Jefferies 2014 Global Healthcare Conference on June 3, 2014 May 27 2014
Nasdaq stocks posting largest percentage increases May 20 2014
SciClone Pharmaceuticals' (SCLN) CEO Friedhelm Blobel on Q1 2014 Results - Earnings Call Transcript May 12 2014
SciClone Pharmaceuticals (SCLN) Q4 2013 Results - Earnings Call Webcast May 12 2014
SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 12 2014
SciClone reports Q1 adjusted EPS 10c, one estimate 8c May 12 2014
SciClone Reports Financial Results for the First Quarter 2014 May 12 2014
SciClone Pharmaceuticals to Report Financial Results for the First Quarter 2014 on May 12th May 05 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK